Zacks Small Cap Research
- Home
- CVKD
as of 02-27-2026 3:46pm EST
$8.30
$0.08
-0.95%
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
| Founded: | 2022 | Country: | United States |
| Employees: | N/A | City: | PONTE VEDRA |
| Market Cap: | 13.3M | IPO Year: | 2022 |
| Target Price: | $32.00 | AVG Volume (30 days): | 48.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | semi-annual |
| EPS: | -5.23 | EPS Growth: | -1308.06 |
| 52 Week Low/High: | $4.91 - $20.39 | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -1.61 | Index: | N/A |
| Free Cash Flow: | -7364087.0 | FCF Growth: | N/A |
AI-Powered CVKD Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 72.87%
72.87%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Cadrenal Therapeutics Inc. (CVKD)
Szot Matthew K
Sell
Chief Financial Officer
CVKD Dec 29, 2025
Avg Cost/Share
$6.97
Shares
9,933
Total Value
$69,233.01
Owned After
0
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Szot Matthew K | CVKD | Chief Financial Officer | Dec 29, 2025 | Sell | $6.97 | 9,933 | $69,233.01 | 0 |
Latest Cadrenal Therapeutics Inc. News
CVKD Breaking Stock News: Dive into CVKD Ticker-Specific Updates for Smart Investing
GlobeNewswire
Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement
📈
AI Sentiment
Highly Positive
8/10
Compare CVKD vs Leading Stocks
See how CVKD stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CVKD Cadrenal Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.